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Abstract
The Global Influenza Hospital Surveillance Network (GIHSN) has established a prospective, active surveillance,
hospital-based epidemiological study to collect epidemiological and virological data for the Northern and
Southern Hemispheres over several consecutive seasons. It focuses exclusively on severe cases of influenza
requiring hospitalization. A standard protocol is shared between sites allowing comparison and pooling of
results. During the 2014–2015 influenza season, the GIHSN included seven coordinating sites from six countries
(St. Petersburg and Moscow, Russian Federation; Prague, Czech Republic; Istanbul, Turkey; Beijing, China; Valencia, Spain;
and Rio de Janeiro, Brazil). Here, we present the detailed epidemiological and influenza vaccine effectiveness findings
for the Northern Hemisphere 2014–2015 influenza season.
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Introduction
Every year, between 5 % and 10 % of adults and 20 – 30 %
of children have symptomatic influenza illness [1, 2], and
3 to 5 million individuals suffer from severe influenza,
leading to 250,000 to 500,000 deaths [2–4]. Influenza
illness can result in hospitalization and death, mainly
among high-risk groups but also in a substantial pro-
portion of previously healthy individuals [5]. In recent
years, especially after the 2009 pandemic season, in-
fluenza surveillance has been expanded, as recom-
mended by the World Health Organization (WHO),
to include additional epidemiological data [6].
The Global Influenza Hospital Surveillance Network
(GIHSN) is an international public-private collaboration
initiated in 2012 by Sanofi Pasteur and the Fundación para
el Fomento de la Investigación Sanitaria y Biomédica de la
Comunitat Valenciana (FISABIO), a regional public health
institution in Valencia, Spain. The aim of the GIHSN is to
improve understanding of influenza epidemiology to
better inform public health policy decisions. It is the first
global network focusing exclusively on severe cases of
influenza requiring hospitalization. The GIHSN runs a
prospective, active surveillance, hospital-based epidemio-
logical study to collect epidemiological and virological
data for the Northern and Southern Hemispheres over
several consecutive seasons. A standardised protocol and
standard operating procedures are shared between sites
allowing comparison and pooling of results [7]. The
GIHSN is coordinated by FISABIO and is made up of sev-
eral country sites affiliated with national health authorities.
Each site coordinates several hospitals in its region. The
network currently includes 27 hospitals coordinated by 7
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sites in 6 countries (St. Petersburg and Moscow, Russian
Federation; Prague, Czech Republic; Istanbul, Turkey;
Beijing, China; Valencia, Spain; and Rio de Janeiro, Brazil).
The surveillance data collected by the GIHSN are used
to describe the circulating strains related to severe disease,
estimate the burden of severe influenza disease, and evalu-
ate the benefit of influenza vaccination to prevent severe
disease. Results have been published from the network’s
first two seasons, 2012–2013 [5, 8] and 2013–2014 [9]. In
this report, we describe the influenza epidemiology and
vaccine effectiveness results from the GIHSN during the
2014–2015 influenza season. Complete data from the
Southern Hemisphere was not available at the time of the
meeting or during analysis and writing, so only data pro-
vided by sites in the Northern hemisphere during the
2014–2015 season are presented.
Methods
Summary of overall methodology
As described in detail elsewhere [7], patients admitted in
the participating hospitals are included, after written con-
sent, if they are residents in the predefined hospital’s
catchment area, present with an acute illness possibly re-
lated to influenza, are not institutionalised, and the onset
of symptoms was within 7 days of admission. Swabs are
collected from patients meeting the inclusion criteria and
tested by reverse transcription-polymerase chain reaction
(RT-PCR) for influenza (Fig. 1). Influenza-positive samples
are sub-typed by RT-PCR to identify A(H1N1)pdm09,
A(H3N2), B/Yamagata-lineage, and B/Victoria-lineage
strains. Vaccine effectiveness is assessed using a test-
negative design in which vaccine coverage is compared
between admissions with and without laboratory-
confirmed influenza.
Epidemiological analysis
Epidemiological and virological data were collected
from 7 coordinating sites and a total of 27 hospitals in 6
countries (Additional file 1). Briefly, eligible admissions
included non-institutionalised residents in the prede-
fined catchment areas of the participating hospitals,
hospitalised in the last 48 h, and with presenting illness
potentially associated with influenza (Additional file 2
and Additional file 3). The study activities were per-
formed over influenza circulation periods defined using
pre-specified criteria (Additional file 3). Nasopharyngeal
swabs (all subjects), pharyngeal swabs (subjects ≥14 years)
or nasal swabs (subjects <14 years) were tested by semi-
quantitative RT-PCR for influenza A (subtypes H3 and
H1pdm09) and B (Yamagata and Victoria lineages). The
distribution of hospital admission according to RT-PCR
result was described by site and risk group. Secondary
outcomes included hospital admissions by subtype for in-
fluenza A(H1N1)pdm09, A(H3N2), and B-lineage, by site
and risk group. The significance of differences among
groups or categories was estimated by the likelihood ratio
test, t-test, or nonparametric tests as required. A P-value
<0.05 was considered to indicate statistical significance.
To describe the major determinants for admission with
influenza (vs. influenza-negative admission), a stepwise
logistic regression model was fitted by including all
risk factors at P < 0.2. Adjusted odds ratios (aORs) for
RT-PCR-positive vs. RT-PCR-negative admissions in
the presence of major risk factors of interest were
Fig. 1 Overview of the methodology used by the GIHSN
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estimated by multivariate logistic regression using
minimal sufficient adjustment sets of covariates identi-
fied as confounders by causal diagrams. To account for
the possible effect of study site, data were fitted to a
random effects logistic regression model including site
as a cluster variable. Likelihood ratio tests were used
to check for the potential effect of clustering by site
[10]. The adjusted effect of site in the probability of in-
fluenza with admission was estimated. Heterogeneity
in the effects of risk factors by influenza strain and site
were quantified using the I2 test. Heterogeneity was
defined as an I2 > 50 % [11, 12]. Further details are pro-
vided elsewhere [5, 7, 8].
Influenza vaccine effectiveness analysis
Influenza vaccine effectiveness (IVE) was estimated as
(1 ˗ OR) × 100, where the OR compared the vaccine
coverage rate between influenza-positive and
influenza-negative patients. Patients were considered
vaccinated if they had received the current season’s
influenza vaccine at least 14 days before symptom on-
set. The types of vaccines used at each site are sum-
marised in Additional file 4. IVE overall (irrespective
of vaccine type) was determined in patients who had
been swabbed within 7 days of the onset of ILI symp-
toms. Records for which outcome, exposure, or con-
founding variables were missing were excluded from
the multivariate IVE analyses. The adjusted IVE was
estimated by logistic regression using a random ef-
fects model with study site as a shared parameter for
the pooled analysis and including week of symptom
onset as a continuous variable, and age group, sex,
hospitalisation in the previous 12 months, presence of
chronic conditions, and smoking habits as potential
confounding factors. A P-value <0.05 was considered
to indicate statistical significance. Heterogeneity in
IVE estimates was assessed using the I2. Potential
sources of heterogeneity, including coordinating site,
age, and influenza subgroup were examined in ad-hoc
analyses. Heterogeneity was defined as low if I2 statis-
tic <25 %, moderate if 25 – 49 %, and high if ≥50 %.
Further details of the methodology are described else-
where [8].
Results
Epidemiology of influenza in the GIHSN during the
2014–2015 influenza season
Patients included in the epidemiology analysis
Twenty thousand five hundred fifty-one eligible ad-
missions were identified between November 16, 2014
and May 23, 2015, of which 9614 met the selection
criteria and were included (Table 1). Based on RT-
PCR, 2177 (23 %) were positive for influenza. Major
reasons for exclusion included no ILI symptoms be-
fore admission (15 %), previous admission fewer than
30 days from the current episode (13 %), admission
more than 7 days after the onset of symptoms (6 %),
recruitment outside periods of continuous admissions
with influenza (6 %).
Influenza viruses identified in admissions
In the 2177 included influenza-positive patients,
A(H3N2) (n = 1243; 57 %) was the most commonly
identified type of influenza, followed by B/Yamagata-
lineage (n = 623; 29 %), A(H1N1)pdm09 (n = 121;6 %),
A not subtyped (106; 5 %), B lineage not determined
(n = 97; 5 %), and B/Victoria-lineage (n = 11; 0.5 %)
(Table 1 and Fig. 2a and b). Mixed influenza infec-
tions were found in 24 cases. Influenza B lineage not
determined were considered B/Yamagata-lineage for
39 cases in Turkey and four in Valencia. Due to the
mixed circulation of B/Yamagata and B/Victoria
lineages in Moscow, this assumption was not applied
at that site to cases where B-lineage was not
determined.
The 2014–2015 influenza season at the GIHSN sites
Influenza was detected over a span of 27 weeks, from
week 47 of 2014 to week 20 of 2015, with the peak at
week 7 of 2015 (Fig. 2). The earliest start of the influenza
season was reported in Beijing, where influenza-positive
admissions occurred over a span of 23 weeks in two
waves, the first due to A(H3N2) and the second due to
B/Yamagata-lineage (Fig. 2). The latest influenza-positive
admission was in St. Petersburg, where continuous
weekly admissions with influenza were observed over a
span of 19 weeks.
A(H3N2) was the most frequently detected influenza
virus in St. Petersburg (44 % of positives), Czech Republic
(56 %), Beijing (60 %), and Valencia (83 %) (Table 1).
B/Yamagata-lineage was the second-most frequently
detected influenza virus in St. Petersburg (43 %), Czech
Republic (27 %), and Beijing (39 %). With the exception of
Beijing and Turkey, A(H3N2) and B/Yamagata-lineage
co-circulated at all sites (Fig. 2). In Turkey, A(H3N2)
accounted for only 8.5 % of positives, and instead, B
influenza viruses predominated (55 %), followed by
A(H1N1)pdm09 (37 %), with co-circulation of these
two viruses (Table 1 and Fig. 2).
Main characteristics of included patients
Overall, all age groups were represented. Approximately
one-third of included admissions were patients less than
5 years of age, one-third were 5 to 64 years of age, and
one-third were 65 years of age or older (Table 2). More
than half of the included patients were male (n = 5417;
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56 %). Most (n = 5867; 61 %) did not have an underlying
chronic condition, and most (n = 6756; 70 %) had not been
hospitalised in the 12 months before the current episode.
Among the 39 % (n = 3747) of admissions in patients with
underlying chronic conditions, the most frequent were
cardiovascular disease (n = 1998; 21 %), chronic respira-
tory conditions (including chronic obstructive pulmonary
disease [COPD; n = 1459] and asthma [n = 446]; 20 %),
diabetes (n = 1048; 11 %), and renal disease (n = 606; 6 %).
Few patients had active neoplasms (3 %), neuromuscular
diseases (3 %), autoimmune diseases (2 %), liver disease
(2 %), or immunodeficiency (1 %).
Just under half (n = 298; 45 %) of the admitted
women 15–45 years of age were pregnant. Obese pa-
tients represented 17 % (n = 1658) of admissions.
Among admissions in adult patients (≥18 years; n = 5066),
1045 (21 %) were current smokers, 1544 (30 %) were
past smokers, and 2477 (49 %) had never smoked.
Among elderly patients (≥65 years; n = 2857), 17 %
(n = 480) had severe functional impairment as de-
fined by a Barthel index <60. Finally, 2013 (21 %)
admissions were in patients that had received the
current season’s influenza vaccine at least 14 days
before the onset of symptoms. Overall, swabs were
obtained within 4 days after the onset of symptoms
onset in 7002 (73 %) of included admissions.
Site-related characteristics of included patients
Patients included in St. Petersburg were younger than
patients included at other sites (Table 2). The difference
Table 1 Selection of patients and results of RT-PCR
St. Petersburg Moscow Czech Republic Turkey Beijing Valencia Total
Category n % n % n % n % n % n % n %
Screened admissions 3164 1934 123 1409 1425 12,496 20,551
Exclusion criteria
Non resident 21 0.7 95 4.9 12 9.8 73 5.2 5 0.4 50 0.4 256 1.2
Institutionalised 14 0.4 14 0.7 2 1.6 17 1.2 2 0.1 800 6.4 849 4.1
Previous discharge <30 days 31 1.0 51 2.6 8 6.5 216 15.3 13 0.9 2283 18.3 2602 12.7
Unable to communicate 20 0.6 47 2.4 2 1.6 125 8.9 0 0.0 782 6.3 976 4.7
Not giving consent 100 3.2 32 1.7 14 11.4 47 3.3 15 1.1 504 4.0 712 3.5
No ILI symptoms ≥5 years of age 19 0.6 25 1.3 1 0.8 131 9.3 18 1.3 2903 23.2 3097 15.1
Admission within 7 days of symptoms onset 181 5.7 150 7.8 4 3.3 110 7.8 44 3.1 745 6.0 1234 6.0
Previous influenza infection 1 0.0 0 0.0 0 0.0 7 0.5 0 0.0 1 0.0 9 0.0
Onset of symptoms to swab >9 days 0 0.0 1 0.1 0 0.0 2 0.1 0 0.0 1 0.0 4 0.0
Sample inadequate 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 5 0.0 5 0.0
Sample lost 0 0.0 0 0.0 0 0.0 0 0.0 1 0.1 1 0.0 2 0.0
Recruited outside periods with continuous
influenza positive admissions
31 1.0 115 5.9 1 0.8 65 4.6 178 12.5 764 6.1 1154 5.6
Included with valid laboratory results 2715 85.8 1400 72.4 79 64.2 614 43.6 1149 80.6 3657 29.3 9614 46.8
RT-PCR result
Influenza negative 2113 77.8 966 69.0 20 25.3 543 88.4 875 76.2 2920 79.8 7437 77.4
Influenza positive 602 22.2 434 31.0 59 74.7 71 11.6 274 23.8 737 20.2 2177 22.6
Subtype and lineagea
A(H1N1)pdm09 47 7.8 30 6.9 7 11.9 26 36.6 1 0.4 10 1.4 121 5.6
A(H3N2) 267 44.3 163 37.6 33 55.9 6 8.5 163 59.5 611 82.9 1243 57.1
A not subtyped 48 8.0 9 2.1 2 3.3 0 0.0 0 0.0 47 6.4 106 4.9
B/Yamagata lineage 258 42.9 175 40.3 16 27.1 0 0.0 109 39.8 65 8.8 623 28.6
B/Victoria lineage 0 0 10 2.3 0 0 0 0.0 1 0.4 0 0.0 11 0.5
B not subtypedb 0 0 52 12.0 2 3.4 39 54.9 0 0.0 4 0.5 97 4.5
Abbreviations: ILI, influenza-like disease; RT-PCR, reverse transcriptase-polymerase chain reaction
aBecause there were 24 mixed infections, each involving two different influenza viruses, the sum by strain may be greater than the number of patients included
with lab results. Percentages are reported by total of influenza-positive cases
bFor Turkey and Valencia, all B not subtyped were assumed to be B/Yamagata lineage based on virus circulation at these sites. This assumption was not applied
for Moscow because of a mixed pattern of influenza B circulation
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in age of included patients was especially marked when
comparing St. Petersburg with the Czech Republic and
Valencia. Patients were most frequently young adults in
Moscow and the Czech Republic. Ages were homoge-
neously distributed in Turkey and Beijing (P = 0.9480).
By contrast, in Valencia most (62 %) admissions were in
elderly patients (≥65 years).
Patients without comorbidities represented 88 % of ad-
missions in St. Petersburg, 89 % in Moscow, 71 % in
Beijing, 37 % in Czech Republic, 30 % in Turkey, and
33 % in Valencia. Of the different chronic conditions,
cardiovascular disease, respiratory disease, and diabetes
were the most common, and their relative importance at
each site corresponded to the proportion of patients
with one or more underlying chronic condition.
In Moscow, among admissions in patients with
known risk factors for influenza, pregnant women
represented the majority of admissions (n = 291;
96 %). Obese patients represented 10 – 15 % of
admissions in St. Petersburg, Moscow, the Czech
Republic, and Beijing, whereas 18 % in Turkey and
26 % in Valencia were obese. The proportion of who
never smoked ranged from 47 – 53 % in adult
(≥18 years) admissions and was similar across sites
(p = 0.1520). The overall proportion of current
smokers, however, differed, with the highest rate
(34 %) in St. Petersburg and Moscow (33 %),
followed by Czech Republic (25 %), Beijing (18 %),
Valencia (16 %), and Turkey (13 %) (p < 0.0001). For
elderly adults, functional impairment status was mild
or minimal in 83–97 % of included admissions at all
sites except Beijing, where 30 % of admissions in
elderly patients had moderate to severe functional
impairment. Rates of influenza vaccination were
below 5 % for all sites except Beijing (11 %) and
Valencia (48 %).
Heterogeneity between sites
The proportion of samples with positive results dif-
fered between sites, from as low as 12 % for Turkey
to as high as 75 % for the Czech Republic (Table 1;
p < 0.0001 by test of homogeneity for equal odds).
This difference persisted after excluding pregnant






























































































































































































































































































































































































































































































































































































































































































































































































































St. Petersburg Moscow Czech Republic
Turkey Beijing Valencia
A(H1N1)pdm09 A(H3N2) A not subtyped B/Yamagata B/Victoria B not subtyped
Epidemiological week
Fig. 2 Admissions with influenza by epidemiological week and virus type, subtype, or lineage overall and by site. B strains included B not
subtyped and mixed influenza infections including influenza B but excluded B/Victoria lineage
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Table 2 Characteristics of included patients overall and by site
St. Petersburg Moscow Czech Republic Turkey Beijing Valencia Total
N = 2715 N = 1400 N = 79 N = 614 N = 1149 N = 3657 N = 9614
Characteristic n % n % n % n % n % n % n %
Age in years, median (range) 3 (0–94) 19 (0–90) 51 (19–91) 12 (0–98) 8 (0–96) 73 (0–106) 21 (0–106)
Age group
0–1 y 714 26.3 137 9.8 0 0.0 112 18.2 76 6.6 476 13.0 1515 15.8
2–4 y 1034 38.1 371 26.5 0 0.0 133 21.7 403 35.1 265 7.2 2206 22.9
5–17 y 357 13.1 171 12.2 0 0.0 80 13.0 147 12.8 72 2.0 827 8.6
18–49 y 426 15.7 632 45.1 38 48.1 38 6.2 106 9.2 221 6.0 1461 15.2
50–64 y 110 4.1 59 4.2 14 17.7 75 12.2 131 11.4 359 9.8 748 7.8
65–74 y 39 1.4 13 0.9 12 15.2 69 11.2 93 8.1 593 16.2 819 8.5
75–84 y 31 1.1 11 0.8 9 11.4 80 13.0 127 11.1 969 26.5 1227 12.8
≥85 y 4 0.1 6 0.4 6 7.6 27 4.4 66 5.7 702 19.2 811 8.4
Sex
Male 1489 54.8 827 59.1 40 50.6 356 58.0 696 60.6 2009 54.9 5417 56.3
Female 1226 45.2 573 40.9 39 49.4 258 42.0 453 39.4 1648 45.1 4197 43.7
Chronic conditions
0 2380 87.7 1246 89.0 29 36.7 182 29.6 820 71.4 1210 33.1 5867 61.0
1 244 9.0 116 8.3 31 39.2 196 31.9 233 20.3 1026 28.1 1846 19.2
>1 91 3.4 38 2.7 19 24.1 236 38.4 96 8.4 1421 38.9 1901 19.8
Previously hospitalised (last 12 months)
No 1781 65.6 1123 80.2 56 70.9 341 55.5 964 85.1 2491 68.1 6756 70.4
Yes 934 34.4 277 19.8 23 29.1 273 44.5 169 14.9 1166 31.9 2842 29.6
Underlying chronic conditions
Cardiovascular disease 140 5.2 68 4.9 29 36.7 215 35.0 218 19.0 1328 36.3 1998 20.8
Chronic obstructive pulmonary disease 51 1.9 19 1.4 6 7.6 153 24.9 137 11.9 1093 29.9 1459 15.2
Asthma 60 2.2 19 1.4 3 3.8 74 12.1 8 0.7 282 7.7 446 4.6
Immunodeficiency/organ transplant 30 1.1 0 0.0 3 3.8 48 7.8 0 0.0 25 0.7 106 1.1
Diabetes 32 1.2 14 1.0 12 15.2 96 15.6 34 3.0 860 23.5 1048 10.9
Renal impairment 18 0.7 26 1.9 4 5.1 61 9.9 12 1.0 485 13.3 606 6.3
Neuromuscular disease 68 2.5 15 1.1 1 1.3 79 12.9 12 1.0 92 2.5 267 2.8
Neoplasm 7 0.3 9 0.6 9 11.4 79 12.9 7 0.6 190 5.2 301 3.1
Cirrhosis/liver disease 34 1.3 21 1.5 5 6.3 19 3.1 5 0.4 118 3.2 202 2.1
Autoimmune disease 13 0.5 14 1.0 4 5.1 22 3.6 0 0.0 122 3.3 175 1.8
Pregnant (women 15–45 y) 0 0.0 291 95.7 1 7.1 1 4.8 0 0.0 5 5.7 298 45.4
Obese (all ages) 263 9.7 162 11.6 12 15.2 109 17.8 155 13.5 957 26.2 1658 17.2
Outpatient consultations last 3 months
0 1215 44.8 492 35.1 23 29.1 113 18.4 4 0.3 649 17.7 2496 26.0
1 895 33.0 314 22.4 19 24.1 100 16.3 697 60.9 678 18.5 2703 28.1
>1 605 22.3 594 42.4 37 46.8 401 65.3 443 38.7 2330 63.7 4410 45.9
Smoking habits (patients ≥18 y)
Never smoker 325 53.3 345 47.9 40 50.6 135 46.7 269 51.4 1363 47.9 2477 48.9
Past smoker 76 12.5 136 18.9 19 24.1 117 40.5 162 31 1034 36.4 1544 30.5
Current smoker 209 34.3 240 33.3 20 25.3 37 12.8 92 17.6 447 15.7 1045 20.6
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results: proportions with positive results were 22 %
for St. Petersburg, 31 % for Moscow, 24 % for Beijing,
and 20 % for Valencia (p < 0.0014 by test of homo-
geneity for equal odds). After excluding pregnant
women, however, proportions were homogenous in St.
Petersburg, Moscow, and Beijing (p < 0.1464 by test of
homogeneity for equal odds). After adjusting for sex,
age, comorbidity, previous admissions, time to swab,
influenza vaccination, and calendar time, the hetero-
geneity of aORs for a positive result were similar to
the unadjusted results (Additional file 5 and Additional
file 6; I2 = 96.4 %; p <0.0001).
Risk of admission with influenza according to age and sex
and variability by influenza virus
Influenza positivity was related to age. Overall,
influenza-positive admissions tended to be older than
influenza-negative admissions (Table 3). Admissions
positive for A(H1N1)pdm09 were younger than those
negative for influenza, those positive for A(H3N2), and
those positive for B/Yamagata-lineage. Also, admissions
positive for A(H3N2) were older than influenza-negative
admissions, those positives for A(H1N1)pdm09, and
those positive for B/Yamagata-lineage (Table 3 and
Fig. 3).
After adjusting for sex, occupational class, comorbidity,
influenza vaccination, time to swab, and the clustering ef-
fect of site, heterogeneity due to strain was significant for
admissions in subjects ≥5 years of age due to a decrease in
aOR with age for admission with A(H1N1)pdm09 (Table 4
and Additional file 7). After excluding admissions with
A(H1N1)pdm09, the aOR for admission with influenza
was homogeneous for elderly patients but heterogeneous
for patients 5–64 years of age (I2 = 75–77 %) due to a
higher aOR for admissions with B/Yamagata-lineage than
for A(H3N2) (Additional file 7).
Female patients had a higher risk than male patients of
being influenza-positive (aOR, 1.21 [95 % CI, 1.09-1.34]),
irrespective of strain (I2 = 0 %). However, after excluding
pregnant women, the risk was more similar for males and
females (aOR, 1.10 [95 % CI, 0.99–1.23]) (Table 4).
Risk of admission with influenza according presence of
comorbidity
Similar proportions of influenza-positive admissions
(882/2177; 41 %) and influenza-negative admissions
(2865/7437; 39 %) had one or more chronic underlying
condition (p = 0.0940) (Table 3). After excluding pregnant
women, 42 % of influenza-positive admissions had comor-
bidity compared to 39 % of influenza-negative admissions
(p = 0.006) (data not shown). The aOR for admission with
influenza was 1.5 (95 % CI, 1.3–1.7) for patients with co-
morbidities, although the values were heterogeneous by
strain (I2 = 63 %) (Table 4) due to a higher aOR for admis-
sion with A(H3N2) or B/Yamagata-lineage in patients with
comorbidities compared to patients with no underlying
conditions (Additional file 8).
Irrespective of the involved strain (I2 = 22 %), the risk
of admission with influenza was significantly increased
in patients with cardiovascular disease (aOR = 1.5 [95 %
CI, 1.3–1.7), asthma (1.4 [95 % CI, 1.0–1.8]), or diabetes
(1.4 [95 % CI, 1.1–1.7]) (Table 4, Fig. 4, and Additional
file 9). The aOR was heterogeneous for the risk of ad-
mission with influenza in patients with COPD (aOR 1.4
[95 % CI, 1.2–1.7]; I2 = 58 %) due to lower aOR for ad-
mission with A(H1N1)pdm09 (Additional file 9). Point
values for aORs were above 1.0 for admission with
influenza for patients with renal, neuromuscular, or
autoimmune disease, but 95 % CIs overlapped 1.0. In
patients with active neoplasms, the overall aOR for
influenza-positive admission was heterogeneous and
not significant (I2 = 56 %; aOR = 1.3 [95 % CI, 0.9–1.8]),
Table 2 Characteristics of included patients overall and by site (Continued)
Functional status impairment (Barthel score; patients ≥65 y)
Total (0–15) 1 1.4 0 0.0 3 11.1 6 3.4 23 10.0 166 7.3 199 7.1
Severe (20–35) 1 1.4 0 0.0 1 3.7 3 1.7 19 8.3 71 3.1 95 3.4
Moderate (40–55) 1 1.4 1 3.3 1 3.7 6 3.4 37 16.1 140 6.2 186 6.6
Mild (60–90) 25 33.8 6 20.0 9 33.3 76 43.2 136 59.1 414 18.3 666 23.8
Minimal (95–100) 46 62.2 23 76.7 13 48.1 85 48.3 15 6.5 1473 65.1 1655 59.1
Sampling time
0–2 days 1351 49.8 655 46.8 20 25.3 125 20.4 324 28.2 896 24.5 3371 35.1
3–4 days 915 33.7 523 37.4 26 32.9 213 34.7 382 33.2 1572 43.0 3631 37.8
5–7 days 449 16.5 221 15.8 24 30.4 239 38.9 358 31.2 1058 28.9 2349 24.4
8–9 days 0 0.0 1 0.1 9 11.4 37 6.0 85 7.4 131 3.6 263 2.7
Influenza vaccination ≥14 days from symptom onset 59 2.2 39 2.8 1 1.3 28 4.6 127 11.1 1759 48.1 2013 20.9
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although for B/Yamagata-lineage, the risk was sig-
nificantly elevated (aOR = 2.2 [95 % CI, 1.1–4.1])
(Additional file 9).
Risk of admission with influenza according pregnancy
A total of 298 included admissions were pregnant
women 15–45 years of age, 291 of whom were included
in Moscow, one in the Czech Republic, one in Turkey,
and five in Valencia (Table 2). No pregnant women were
included in Beijing. Non-pregnant women in this age
group accounted for another 359 included admissions,
of which 197 were in St. Petersburg, 13 in Moscow, 13
in the Czech Republic, 20 in Turkey, 33 in Beijing, and
83 in Valencia (data not shown).
The probability of laboratory-confirmed influenza was
higher in included pregnant women than included same
age non-pregnant women (54 % vs. 24 %; p < 0.0001;
data not shown). After taking into account clustering by
site (and not considering data from Beijing), the crude
OR of admission with influenza was 3.5 (95 % CI, 2.2–
5.3) (Table 4). This crude estimated OR was higher in
pregnant women with associated comorbidity (OR 7.1
[95 % CI, 3.1–16.2]), with moderate evidence of an inter-
action between comorbidity and pregnancy before ad-
justment (p = 0.0659) and a significant interaction after
adjustment (p < 0.0001). Taking into account the modify-
ing effect of associated comorbidity, the aOR for admis-
sion with influenza in pregnant women was 4.3 (95 % CI,
2.7–6.9) in presence of associated comorbidity and 2.1
(95 % CI, 1.4–3.0) for pregnant women with no comorbid-
ity. In both cases, the values were homogenous (I2 = 0 %)
for A(H3N2), A(H1N1)pdm09, and B/Yamagata-lineage
infections.
The probability of admission with influenza was higher
in all three trimesters for pregnant women without asso-
ciated comorbidities than for non-pregnant women in
the same age group without comorbidity. In pregnant
women with comorbidities, the risk of admission with
influenza was highest in the first trimester (Fig. 5 and
Additional file 10).
Risk of admission with influenza and complications by strain
Intensive care unit (ICU) admissions, extracorporeal
membrane oxygenation, and mechanical ventilation were
more frequent for influenza-negative than for influenza-
positive admissions (p ≤ 0.002), whereas rates of in-
hospital death were similar (p = 0.3460) (Table 5). By
strain, the point estimate of rates of ICU admission and
extracorporeal membrane oxygenation were higher in
admissions with A(H1N1)pdm09, although differences
were not significant. In contrast, rates of in-hospital
death were significantly higher in admissions with
A(H3N2) (p = 0.0080). Less than 4 % of admissions in
these categories experienced a severe outcome. Finally,
length of stay did not differ between influenza-positives
and influenza-negative admissions for influenza overall
or between strains (Table 5).
Exacerbation of chronic obstructive pulmonary dis-
ease, respiratory failure, exacerbation of asthma, and
bronchiolitis were more frequently reported for
influenza-positive admissions than for influenza-negative
admissions (Table 5). These were associated with
A(H3N2), except in the case of bronchiolitis, where the
proportions for admission with all three strains
(A(H3N2), A(H1N1)pdm09, and B/Yamagata-lineage)




























A(H1N1)pdm09 (n=121; 6%) A not subtyped (n=106; 5%) 
B/Yamagata (n=665; 30%)
Age group (years of age) 
A(H3N2) (n=1243; 57%)
B/Victoria (n=11; 0.5%) B not subtyped (n=54; 2%)
Fig. 3 Proportion of admissions by strain and age group
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admissions. Cardiovascular events were more frequently
reported for admissions with influenza A(H3N2) than
for admissions with influenza A(H1N1)pdm09 or B (OR
1.3 [95 % CI, 1.1–1.6]; p = 0.0004; data not shown),
whereas, shock was more frequent in admissions with
influenza A(H1N1)pdm09 (adjusted p < 0.0001; Table 5).
Figure 6 shows the estimated marginal probabilities
by strain and age for severe outcomes after adjusting
by sex, comorbidity, calendar time, age, and cluster-
ing by site. We found several non-significant associa-
tions: A(H1N1)pdm09 was associated with intensive
care unit admission and shock; A(H3N2) was
Table 4 Subject characteristics and risk of admission with influenza
All admissions Influenza-positive Crude OR Heterogeneity
by strain (I2)a
aORb
N = 9164 N = 2177
Characteristic n n % Value 95 % CI Value 95 % CI
Age
0–1 y 1515 144 9.5 1.00 - 32.5 % 1.00 -
2–4 y 2206 429 19.4 2.30 1.88-2.81 0.0 % 2.14 1.74-2.64
5–17 y 827 280 33.9 4.87 3.90-6.10 73.3 % 4.34 3.42-5.51
18–49 y 1461 423 29.0 3.88 3.16-4.77 59.2 % 3.11 2.49-3.90
50–64 y 748 191 25.5 3.26 2.57-4.14 72.5 % 4.08 3.11-5.36
65–74 y 819 211 25.8 3.30 2.62-4.17 67.8 % 4.99 3.76-6.64
75–84 y 1227 294 24.0 3.00 2.42-3.72 62.4 % 4.51 3.43-5.92
≥85 811 205 25.3 3.22 2.55-4.07 71.2 % 4.79 3.59-6.40
Sexc
Male 5417 1141 21.1 1.00 - 0.0 % 1.00 -
Female 4197 1036 24.7 1.24 1.13-1.37 0.0 % 1.21 1.09-1.34
Female non-pregnant 3899 876 22.5 1.11 1.00-1.22 0.0 % 1.10 0.99-1.23
Other risk factors (excludes pregnant women)
Comorbidityd 3709 856 23.1 1.15 1.04-1.27 62.8 % 1.48 1.30-1.69
Cardiovascular disease 1996 468 23.4 1.17 1.04-1.33 22.2 % 1.47 1.25-1.72
Chronic obstructive pulmonary disease 1458 306 21.0 1.02 0.88-1.17 57.6 % 1.39 1.15-1.68
Asthma 440 96 21.8 1.07 0.84-1.35 0.0 % 1.37 1.04-1.80
Immunosuppression 106 14 13.2 0.58 0.33-1.03 0.0 % 0.76 0.40-1.46
Diabetes 1048 234 22.3 1.10 0.94-1.29 0.0 % 1.36 1.10-1.70
Renal disease 588 129 21.9 1.08 0.88-1.32 48.2 % 1.23 0.95-1.59
Neuromuscular 167 52 31.1 0.93 0.68-1.26 38.9 % 1.13 0.80-1.58
Neoplasm (active) 301 63 20.9 1.01 0.76-1.35 55.6 % 1.29 0.92-1.81
Liver disease 200 33 16.5 0.76 0.52-1.11 50.8 % 0.79 0.52-1.21
Autoimmune disease 161 39 24.2 1.22 0.85-1.77 0.0 % 1.44 0.95-2.18
Obesee 1620 337 20.8 1.0 0.9-1.2 0.0 % 0.87 0.73-1.03
Pregnancyf 298 160 53.7 3.45 2.23-5.34 0.0 % 2.08 1.43-3.03
Associated comorbidity 38 26 68.4 7.07 3.09-16.18 0.0 % 4.29 2.65-6.94
No comorbidity 260 126 48.5 3.05 2.08-4.47 0.0 % 1.80 1.22-2.66
aStrains considered: A(H3N2), A(H1N1)pdm09 and B/Yamagata
bMinimal sufficient adjustment sets for estimating the exposure or risk factor effect on the risk of admission with influenza vs. all included admissions without
underlying conditions or pregnant
cFemale or female non-pregnant vs. male. aORs were adjusted for age, occupational social class group, underlying comorbidity, obesity, influenza vaccination, time
to swab, calendar time, and site as a clustering factor
dOne or more underlying conditions or individual comorbidities vs. no comorbidity. aORs were adjusted for sex, occupational social class group, obesity, influenza
vaccination, time to swab, calendar time, and site as a clustering factor
eaOR adjusted for sex, age, occupational social class group, influenza vaccination, time to swab, calendar time, and site as a clustering factor
fWomen 15-45 years of age included in Moscow, St. Petersburg, Czech Republic, Turkey and Valencia. aOR adjusted for smoking habits, time to swab, calendar
time, comorbidity, and site as a clustering factor. For results stratified by comorbidity, aORs were adjusted by the same covariates and were estimated taking into
account the interaction between pregnancy and comorbidity
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associated with an increased probability of COPD
exacerbation, respiratory failure, cardiovascular com-
plications, and death; B/Yamagata-lineage was related
to respiratory failure; and all three strains were re-
lated to death at both extremes of age (Fig. 6). We
found similar non-significant associations for compli-
cations when influenza-negative admissions were in-
cluded (Additional file 11).
Influenza vaccine effectiveness in the GIHSN during the
2014–2015 influenza season
Patients included in the influenza vaccine effectiveness
analysis
After applying exclusions related to vaccine contraindi-
cation (egg allergy and <6 months of age), 8455 speci-
mens collected from November, 2014 through May,
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Fig. 5 Predicted probability of admission with influenza in non-pregnant 15 – 45 years old women and by pregnancy trimester in same
age pregnant women
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specimens, 2027 (24 %) were positive for influenza, of
which 1165 (57 %) were positive for A(H3N2), 104 (5 %)
for A(H1N1)pdm09, and 625 (31 %) for B Yamagata-
lineage (Table 6). Overall, 22 % (n = 446) of influenza-
positive admissions and 24 % (n = 1556) of influenza-
negative admissions were vaccinated (p = 0.042) (Table 7).
The proportion of patients vaccinated with the seasonal
influenza vaccine in 2014–2015 ≥ 14 days before symp-
tom onset was 3 % in St. Petersburg (n = 43) and
Moscow (n = 30), 5 % in Turkey (n = 22), 11 % (n = 94)
in Beijing, and 54 % (n = 1367) in Valencia (data not
shown).
Overall, 1709 of 2002 (85 %) influenza vaccinations
among study patients were both self-reported and con-
firmed from registries. Self-report captured 156 of 2002
vaccinations (8 % overall, 67 % in Moscow, 8 % in
Turkey, 1 % in Beijing, and 7 % in Valencia; data not
shown). Another 137 patients (7 % overall, 12 % in St.
Petersburg, 42 % in Turkey, and 7 % in Valencia; data
not shown) with vaccination records failed to self-report
vaccination.
The proportion of participants with comorbidity
was significantly higher in vaccinated than in non-
vaccinated admissions (82 % vs. 30 %, p < 0.001)
(Table 7). Vaccination was also more common among
elderly (median age = 79 years for vaccinated patients
vs. 15 years for non- vaccinated patients, p < 0.001),
obese patients (28 % obese for vaccinated patients vs.
15 % for non-vaccinated patients, p < 0.001), elderly
patients with impairment or minimal functional im-
pairment (28 % impaired for vaccinated patients vs.
15 % for non-vaccinated patients, p < 0.001), patients
with outpatient visits (83 % for vaccinated patients vs.
72 % for non-vaccinated patients, p < 0.001), and pa-
tients admitted to a hospital in the previous
12 months (38 % for vaccinated patients vs. 29 % for
non-vaccinated patients, p < 0.001) (Table 7). Three
(0.1 %) pregnant women had received the current
season’s vaccine.
Most patients vaccinated in 2014–2015 reported prior
vaccination: 87 % of vaccinated patients had received the
2013–2014 vaccine (p < 0.001) and 73 % had received the
2012–2013 vaccine (p < 0.001) (Table 7). Both the 2011-
2012 and 2012–2013 vaccines were received by 90 % (26/
29) of cases and 77 % (89/116) of controls (p = 0.12).
Influenza vaccine effectiveness
Against all-age influenza-related hospitalisation, the

































































































Fig. 6 Predicted probability of severe outcome by strain (not subtyped, mixed influenza with influenza infections and B/Victoria lineage excluded)
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[CI], −17–12), and the adjusted IVE was 22 % (95 % CI,
8–33) (Table 6). Age at admission, presence of comor-
bidities, and degree of functional impairment were the
covariates with the largest confounding effect on crude
IVE (data not shown), raising the crude IVE with
adjustment.
The adjusted IVE for patients of all ages was higher
against influenza B (31 % [95 % CI, 2–52]) than for influ-
enza A(H3N2) (20 % [95 % CI, 4–33]) and influenza
A(H1N1)pdm09 (27 % [95 % CI, −82–71]) (Table 6), al-
though confidence intervals overlapped (I2 for adjusted
IVE across strains = 0 %, p = 0.762; data not shown).
Age-specific estimates suggested that vaccination
against any influenza was less effective in patients
<65 years of age (IVE [95 % CI] = −5 % [−38–20])
than in patients ≥65 years of age (IVE = 24 % [95 %
CI, 9–37]) (P value for effect modification of age =
0.054). This pattern of lower IVE in the younger
patients was consistent across strains, but only age-
specific estimates for A(H3N2) were significantly dif-
ferent (Table 6).
Estimates were similar when the analyses were re-
stricted to patients belonging to the target group for
vaccination (crude IVE against overall influenza for all
ages = 13 % [95 % CI, −2–26], adjusted IVE = 23 % [95 %
CI, 8–35]) (Table 6).
IVE estimates were consistently higher for recipients
of the 2012–2013 influenza vaccine, the 2013–2014 in-
fluenza vaccine, or both vaccines than for recipients of
only the current season’s vaccine, although confidence
intervals overlapped (Additional file 12).
Statistical heterogeneity across sites in the estimates of
IVE against influenza-related hospitalisation was relatively
low, with site-specific adjusted point estimates ranging
from -27 – 35 % [I2 = 0 %; P = 0.835) (Additional file 13).
Sensitivity analyses were performed to assess the ef-
fects of excluding pregnant women, participants vacci-
nated within 14 days before symptom onset, and
without medical vaccination records. In all cases, IVE es-
timates remained similar to those of primary analysis
(Additional file 14). Further sensitivity analyses using
various statistical methods to account for potential data
Table 6 IVE for all cases and for targeted groups only by age and strain
Influenza-positive Influenza-negative Crude IVE Adjusted IVE
Population Strain Age Total Vaccinated Total Vaccinated Percent (95 % CI) P interaction Percent (95 % CI) P interaction
Overall Any Any 2027 446 6428 1556 -1 (-17, 12) 22 (8, 33)
<65 y 1334 78 4299 289 -4 (-36, 20) 0.090 -5 (-38, 20) 0.054
≥65 y 693 368 2129 1267 21 (5, 34) 24 (9, 37)
A(H3N2) Any 1165 356 6428 1556 -6 (-24, 10) 20 (4, 33)
<65 y 630 50 4299 289 -15 (-59, 17) 0.036 -16 (-64, 17) 0.031
≥65 y 535 306 2129 1267 24 (7, 37) 25 (8, 39)
A(H1N1) Any 104 7 6428 1556 25 (-85, 69) 27 (-82, 71)
<65 y 91 3 4299 289 16 (-173, 74) 0.996 21 (-161, 76) 0.993
≥65 y 13 4 2129 1267 47 (-128, 88) 59 (-83, 91)
B/Yamagata Any 625 57 6428 1556 16 (-17, 39) 31 (2, 52)
<65 y 509 20 4299 289 7 (-51, 42) 0.266 29 (-17, 58) 0.273
≥65 y 116 37 2129 1267 38 (-2, 62 33 (-12, 61)
Targeted groups only Any Any 1670 425 5077 1462 13 (-2, 26) 23 (8, 35)
<65 y 977 57 2948 195 -21 (-70. 14) 0.037 -12 (-58, 20) 0.019
≥65 y 693 368 2129 1267 26 (16, 42) 28 (14, 41)
H3N2 Any 994 344 5077 1462 13 (-4, 28) 22 (5, 36)
<65 y 459 38 2948 195 -12 (-65, 24) 0.051 -20 (-80. 21) 0.030
≥65 y 535 306 2129 1267 27 (11, 41) 28 (11, 42)
H1N1 Any 84 6 5077 1462 44 (-58, 80) 46 (-52, 81)
<65 y 71 2 2948 195 33 (-198, 85) 0.793 39 (-167, 86) 0.770
≥65 y 13 4 2129 1267 47 (-128, 88) 50 (-111, 89)
B/Yamagata Any 486 49 5077 1462 21 (-18, 46) 30 (-5, 53)
<65 y 370 12 2948 195 -8 (-105, 44) 0.139 8 (-79, 53) 0.250
≥65 y 116 37 2129 1267 38 (-2, 62) 33 (-12, 60)
Abbreviation: IVE influenza vaccine effectiveness
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Table 7 Characteristics of patients included in the primary analysis by vaccination status
Risk variables Category Unvaccinated Vaccinated P value
n % N %
Number of patients, n (%) Controls 4872 75.5 1556 77.7 0.042
Cases 1581 24.5 446 22.3
Age (y) Median (range) 14.6 (0.8-84.0) 78.7 (9.0-91.9) <0.001
Age group, n (%) 6–11 mo 496 7.7 3 0.1
1–4 y 2120 32.9 49 2.4
5–17 y 712 11.0 102 5.1
18–49 y 1347 20.9 75 3.7
50–64 y 591 9.2 138 6.9
65–74 y 388 6.0 416 20.8
75–84 y 512 7.9 704 35.2
≥85 y 287 4.4 515 25.7
Female, n (%) - 2825 43.8 843 42.1 0.188
Comorbidities, n (%) None 4505 70 366 18.3 <0.001
1 1077 16.7 647 32.3
>1 871 13.5 989 49.4
Pregnant, n (%) - 294 4.6 3 0.1 <0.001
Obesity, n (%) - 982 15.2 564 28.2 <0.001
Morbid obesity, n (%) - 86 1.3 54 2.7 <0.001
Previous hospitalisation within 12 months, n (%) - 1887 29.2 761 38 <0.001
GP visit within 3 months, n (%) None 1815 28.1 343 17.1 <0.001
1 2027 31.4 389 19.4
>1 2606 40.4 1272 63.5
Smoking, n (%) Current 1527 23.7 225 11.2 <0.001
Past 1069 16.6 742 37.1
Never 3856 59.8 1035 51.7
Functional impairment in ≥65 y, n (%) None or minimal 619 54.2 1021 62.4 <0.001
Mild 324 28.4 330 20.2
Moderate 95 8.3 88 5.4
Severe 32 2.8 62 3.8
Total 72 6.3 123 7.5
Sampling interval (days) Median (range) 3 (1-7) 4(1-7) <0.001
Sampling interval, n (%) ≤4 d 3703 57.4 990 49.5 <0.001
5-7 d 2587 40.1 936 46.8
8-9 d 163 2.5 76 3.8
Site, n (%) St. Petersburg 2138 33.1 59 2.9 <0.001
Moscow 1306 20.2 39 1.9
Turkey 503 7.8 26 1.3
Beijing 996 15.4 127 6.3
Valencia 1510 23.4 1751 87.5
Vaccinated, n (%)
In 2012–2013 473 7.5 1471 73.3 <0.001
In 2013–2014 513 8.1 1722 87.1 <0.001
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clustering by site showed consistent results, with no evi-
dence of heterogeneity (I2 = 0 %) in estimates of IVE
across methods (Additional file 15).
Discussion
According to data collected by active surveillance
within the GIHSN sites, the 2014–2015 influenza sea-
son was characterised by a predominance of A(H3N2)
and B/Yamagata-lineage, and to a lesser extent,
A(H1N1)pdm09, while B/Victoria-lineage was rela-
tively rare. Reports of severe influenza, defined as
hospitalisation with laboratory (i.e., PCR)-confirmed influ-
enza, spanned 6 months and affected all ages, although
influenza-related admissions were most common in older
individuals. Among patients with laboratory-confirmed in-
fluenza, those with A(H1N1)pdm09 were younger than
those with A(H3N2) or B/Yamagata-lineage, whereas
those with B/Yamagata-lineage were most frequently
young and middle-aged adults. This pattern of influenza
circulation is consistent with that reported by the WHO
[13]. Likewise, the age distribution of the A(H1N1)pdm09,
A(H3N2) and B/Yamagata-lineage strains agrees with
others’ reports [14, 15].
According to our data, comorbidity increased the
risk of admission with influenza, irrespective of the
strain involved. This was also the case for pregnant
women. Furthermore, the combination of pregnancy
and comorbidity increased the risk of admission
several-fold, suggesting an interaction. Remarkably,
however, nearly 60 % of eligible admissions with in-
fluenza were patients without known risk factors.
The probability of ICU admission and shock were
higher in patients infected with A(H1N1)pdm09 than
with other strains. Also, A(H3N2) infection was associ-
ated with respiratory failure and cardiac complications,
whereas B/Yamagata-lineage was associated with an in-
creased probability of respiratory failure. Influenza infec-
tion overall was associated with in-hospital death at both
age extremes. These findings agree with other reports
[15–17], although there may be differences in the abso-
lute percentage of admissions with influenza in patients
with comorbidity, patterns of severity, lengths of hospital
stay, rates of ICU admission, use of supportive measures,
or estimates of in-hospital death rates [15, 18, 19].
Although vaccination coverage was low at the partici-
pating sites (2.8–48 %; average 20.9 %), we found that
vaccination conferred a low to moderate protective ef-
fect (adjusted IVE = 22 %). This protective effect was
greater for adults ≥65 years of age than for adults
<65 years of age and was greater for B/Yamagata-lineage
than for A(H3N2).
The low influenza vaccine effectiveness for the 2014–
2015 season is similar to others’ reports and appears to
be due mostly to a mismatch between the main
A(H3N2) circulating strain and the vaccine strain
[20–23]. Across all strains, the IVE was lower in young
patients, although only age-specific estimates for
A(H3N2) were significantly different due to few cases of
B/Yamagata-lineage and A(H1N1)pdm09 and a higher
IVE in patients vaccinated during the 2012–2013, 2013–
2014, or both seasons than in those vaccinated during
the 2014–2015 season, a finding also reported by others
[24]. This lower IVE in young patients, however, con-
trasts with previous reports where the opposite was
found [25]. Thus, there appears to be variability in the
interference or protection conferred by vaccination in
previous seasons. This could be explained by the differ-
ences between the various strains circulating in different
seasons and their distance from the vaccine strains,
combined with inhibition of the immunological response
when the vaccine strains are similar to those in previous
seasons’ vaccines [26].
Limitations and considerations
Our results are to be interpreted with caution due to the
heterogeneity and bias of multi-centric observational
studies. We assumed heterogeneity in the circulating
strains, socio-demographic diverse populations observed,
their health care seeking behaviour, the characteristics of
the different health care systems involved, the types of
participating hospitals, and by calendar time along the
season. We took account of this heterogeneity by thor-
oughly describing the season, the sites, and included ad-
missions, as well as by quantifying the heterogeneity of
our estimates. In this way, we are able to visualise the
relative impact of the different influenza strains on di-
verse risk factors, including age, comorbidity, pregnancy,
and obesity [12]. Furthermore, we restricted our analysis
to periods with influenza circulation [27], took into ac-
count risk by calendar date [28], as well as the clustering
effect of site [10] by adjusting and modelling and, finally,
compared PCR-detected influenza-positive admissions
with influenza-negative admissions. We consider this a
reasonable approach for describing the effect of influ-
enza in individuals according to their risk profile [29]. In
addition, to reduce bias and to allow us to describe the
severe consequences of community-acquired influenza,
we accepted only data from patients admitted within
7 days of onset of ILI symptoms and for whom swabbing
was performed within 48 h of admission.
Even with a large dataset as the one accrued annually
by the GIHSN sites, small numbers are a limitation.
Splitting the data by strain and risk group can decrease
group sizes, so that sufficient power is available only for
detecting large differences (i.e., OR ≥2). This limitation
can be only dealt with by increasing the number of par-
ticipating sites and by pooling data across influenza
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seasons. In fact, the GIHSN continues to grow, and data
pooling across seasons is underway.
Most hospital studies rely on the criteria of the phys-
ician providing care for influenza confirmation and em-
ploy historical database searching [15, 17, 18, 30–32].
This combined with different case definitions and la-
boratory methods can complicate comparisons be-
tween sites and seasons and between different studies.
Our approach of using active surveillance, a shared
core protocol, and PCR confirmation of influenza
avoids these limitations. This approach has very re-
cently begun to be employed by others and for other
respiratory viruses [33].
Conclusions
This report describes the results from the GIHSN during
the 2014–2015 influenza season that were presented at
the 2015 GIHSN Annual Meeting. During the 2014–
2015 influenza season, the network included 27 hospitals
in six countries (Russian Federation, Czech Republic,
Turkey, China, Spain, and Brazil). This offered us the
opportunity to describe the characteristics of severe dis-
ease related to influenza by time, person, and strain and
to describe IVE across a wide geographical area in the
Northern Hemisphere.
We found that influenza is associated with severe
outcomes during an extended period in the Northern
Hemisphere and that comorbidity and pregnancy were
significant risk factors for severe influenza illness. The
distribution and impact of the three influenza virus
types (A(H1N1)pdm09, A(H3N2), and B) were similar
to others’ reports. An important finding was that ap-
proximately 60 % of influenza-related hospital admissions
were in healthy subjects with no known comorbidity.
Our results support the current WHO recommenda-
tions on the use of influenza vaccine [4], although for
the 2014–2015, IVE was low due to a significant mis-
match between the circulating and vaccine viruses. We
also found that IVE was affected by age and the circulat-
ing strain. These findings highlight the need to develop
vaccines that are more effective and cover a broader
spectrum of influenza viruses.
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